No Data
No Data
Express News | Star closing review: The Military Industry Sector once again strengthened while the Innovative Drugs Sector collectively declined.
Yifang Bio (688382): Core products have made significant research and development progress, with a rich pipeline reserve.
Yifang Biological disclosed its 2024 annual report and the first quarter report for 2025, achieving a revenue of 0.169 billion yuan for the entire year of 2024, a year-on-year decrease of 9.02%; the net income attributable to the parent company was -0.24 billion yuan, a year-on-year reduction in losses of 15.41%.
Express News | The Innovative Drugs Concept has experienced a collective drop, with BEIGENE falling over 8%.
Express News | Yifang Biology's block trade today was conducted at a discount for 3.4468 million shares, with a transaction value of 65.6263 million yuan.
Express News | Star closing review: The Military Industry and Software Sectors strengthened, while the Innovative Drugs Sector collectively declined.
Yifang Biotechnology (688382): Commercialization is advancing steadily, and the innovative pipeline demonstrates BIC potential.
Event overview: The company released the 2024 annual report and the Q1 report for 2025: The company achieved revenue of 0.169 billion yuan for the year 2024 (-9.02%), with net income of -0.24 billion yuan, a year-on-year reduction in loss of 15.4.